NO20032086L - Adjuvant combination formulations - Google Patents

Adjuvant combination formulations

Info

Publication number
NO20032086L
NO20032086L NO20032086A NO20032086A NO20032086L NO 20032086 L NO20032086 L NO 20032086L NO 20032086 A NO20032086 A NO 20032086A NO 20032086 A NO20032086 A NO 20032086A NO 20032086 L NO20032086 L NO 20032086L
Authority
NO
Norway
Prior art keywords
combination formulations
adjuvant combination
adjuvant
formulations
combination
Prior art date
Application number
NO20032086A
Other languages
Norwegian (no)
Other versions
NO20032086D0 (en
Inventor
Michael Hagen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20032086D0 publication Critical patent/NO20032086D0/en
Publication of NO20032086L publication Critical patent/NO20032086L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20032086A 2000-11-10 2003-05-09 Adjuvant combination formulations NO20032086L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24710000P 2000-11-10 2000-11-10
US33034501P 2001-10-18 2001-10-18
PCT/US2001/046943 WO2002038177A2 (en) 2000-11-10 2001-11-08 Adjuvant combination formulations

Publications (2)

Publication Number Publication Date
NO20032086D0 NO20032086D0 (en) 2003-05-09
NO20032086L true NO20032086L (en) 2003-07-07

Family

ID=26938452

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032086A NO20032086L (en) 2000-11-10 2003-05-09 Adjuvant combination formulations

Country Status (26)

Country Link
US (2) US20040156820A1 (en)
EP (1) EP1343527A2 (en)
JP (2) JP2004523483A (en)
KR (1) KR100863368B1 (en)
CN (1) CN1533285A (en)
AU (2) AU2597202A (en)
BG (1) BG107798A (en)
BR (1) BR0115271A (en)
CA (1) CA2429000A1 (en)
CZ (1) CZ20031225A3 (en)
EA (1) EA004744B1 (en)
EE (1) EE200300172A (en)
EG (1) EG24378A (en)
GE (1) GEP20074077B (en)
HR (1) HRP20030355A2 (en)
HU (1) HUP0600589A2 (en)
IL (1) IL155690A0 (en)
IS (1) IS6809A (en)
MX (1) MXPA03004071A (en)
NO (1) NO20032086L (en)
NZ (1) NZ525887A (en)
PE (1) PE20020530A1 (en)
PL (1) PL366031A1 (en)
SK (1) SK5482003A3 (en)
TW (1) TWI239848B (en)
WO (1) WO2002038177A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
SG149039A1 (en) 2003-12-17 2009-01-29 Elan Pharm Inc Ass IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
WO2006047670A2 (en) * 2004-10-26 2006-05-04 Wyeth Methods for assessing antibodies to neurodegenerative disease-associated antigens
KR100878585B1 (en) 2006-06-16 2009-01-15 국립암센터 A cancer sensitizer comprising glucosamine, glucosamine derivatives or salts thereof
WO2010016912A2 (en) * 2008-08-07 2010-02-11 Mercia Pharma, Llc Immunotherapeutic compositions for the treatment of alzheimer's disease

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US6294322B1 (en) 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
US5939074A (en) 1986-12-30 1999-08-17 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptide antigens
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5013548A (en) 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5993819A (en) 1987-09-08 1999-11-30 Duke University Synthetic vaccine for protection against human immunodeficiency virus infection
US5019387A (en) 1987-09-08 1991-05-28 Duke University Production of antibodies to HIV
US5223254A (en) * 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
CA1340506C (en) * 1987-11-24 1999-04-20 Nicholas H. Carbonetti Production of gonorrheal pi proteins and vaccines
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990005147A1 (en) 1988-11-10 1990-05-17 Genetics Institute, Inc. Natural killer stimulatory factor
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
DE3934366A1 (en) * 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus VACCINE FOR PROTECTION AGAINST HIV VIRUS INFECTIONS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A DIAGNOSTIC AND IMMUNOTHERAPEUTIC
DK0671947T3 (en) 1991-12-02 2000-07-24 Univ Texas Preparations for triggering cytotoxic T lymphocyte responses to viruses
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
US5679356A (en) * 1992-07-08 1997-10-21 Schering Corporation Use of GM-CSF as a vaccine adjuvant
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
HU219056B (en) * 1993-03-23 2001-02-28 Smithkline Beecham Biologicals Sa Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
US5723130A (en) * 1993-05-25 1998-03-03 Hancock; Gerald E. Adjuvants for vaccines against respiratory syncytial virus
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
AUPM543894A0 (en) * 1994-05-04 1994-05-26 Commonwealth Scientific And Industrial Research Organisation An adjuvant
US5679256A (en) * 1994-06-20 1997-10-21 Rose; Jane Anne In-situ groundwater clean-up and radionuclide disposal method
ES2257744T3 (en) * 1994-10-05 2006-08-01 Vanderbilt University INTERLEUQUINA-12 AS AN ASSISTANT FOR VACCINES AGAINST PARAMYXOVIRIDAE.
US5939075A (en) * 1994-11-04 1999-08-17 The United States Of America As Represented By The Secretary Of The Army Mutants of Brucella melitensis
JP3958360B2 (en) * 1995-02-24 2007-08-15 キャンタブ ファーマシューティカルズ リサーチ リミティド Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US6613337B1 (en) * 1997-02-12 2003-09-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
JPH09124697A (en) * 1995-11-01 1997-05-13 Toagosei Co Ltd Peptide and monoclonal antibody
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5762943A (en) * 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
AU724743B2 (en) * 1996-05-31 2000-09-28 Genetics Institute, Llc IL-12 as an adjuvant for Bordetella Pertussis vaccines
US6024965A (en) 1996-10-18 2000-02-15 Erasums University Rotterdam Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US6350456B1 (en) * 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
IS4518A (en) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group New vaccine formulation
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6488936B1 (en) * 1998-02-12 2002-12-03 Wyeth Immunogenic composition of interleukin-12 (IL-12), alum, herpes simplex viral (HSV) antigen, and method thereof
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
GB9907860D0 (en) * 1999-04-07 1999-06-02 Smithkline Beecham Biolog Novel compounds
TR200103266T2 (en) 1999-05-13 2002-01-21 American Cyanamid Company Auxiliary combination formulations
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging

Also Published As

Publication number Publication date
AU2597202A (en) 2002-05-21
MXPA03004071A (en) 2003-09-04
HRP20030355A2 (en) 2005-04-30
IL155690A0 (en) 2003-11-23
HUP0600589A2 (en) 2006-11-28
KR100863368B1 (en) 2008-10-13
PE20020530A1 (en) 2002-06-18
EA004744B1 (en) 2004-08-26
US20070025959A1 (en) 2007-02-01
IS6809A (en) 2003-05-07
EE200300172A (en) 2003-06-16
AU2002225972B2 (en) 2006-06-29
KR20040043098A (en) 2004-05-22
JP2010001304A (en) 2010-01-07
TWI239848B (en) 2005-09-21
EG24378A (en) 2009-03-26
US20040156820A1 (en) 2004-08-12
CZ20031225A3 (en) 2003-10-15
EP1343527A2 (en) 2003-09-17
NZ525887A (en) 2005-08-26
NO20032086D0 (en) 2003-05-09
BG107798A (en) 2004-07-30
BR0115271A (en) 2005-12-13
PL366031A1 (en) 2005-01-24
CA2429000A1 (en) 2002-05-16
SK5482003A3 (en) 2004-03-02
WO2002038177A3 (en) 2003-01-16
JP2004523483A (en) 2004-08-05
EA200300557A1 (en) 2004-04-29
GEP20074077B (en) 2007-03-26
WO2002038177A2 (en) 2002-05-16
CN1533285A (en) 2004-09-29

Similar Documents

Publication Publication Date Title
DK1317177T3 (en) Disinfectant formulations
AR028291A1 (en) OPHTHALM FORMULATIONS
EE05421B1 (en) Fulvestrant formulations
NO20026175L (en) vaccine Composition
DK1199054T3 (en) liquefracture handpiece
DE60125859D1 (en) polisher
DE60109664D1 (en) polishing composition
PT1139764E (en) ADJUVANT COMPOSITION
DK1265633T3 (en) The vaccine adjuvant
DE50114386D1 (en) NG
ATE263487T1 (en) LIQUID FORMULATIONS
IS6398A (en) formulations
DE60122236D1 (en) polisher
DZ3495A1 (en) AGROCHEMICAL FORMULATIONS
ATE268116T1 (en) MESOTRION FORMULATIONS
ATE270044T1 (en) FUNGICIDAL FORMULATION
NO20032086L (en) Adjuvant combination formulations
NO20030946D0 (en) Medical compositions
FI20010860A0 (en) projection surface
ITLT20000004U1 (en) NACOL 36/42
IT251671Y1 (en) "MECHANICAL HAND".
FIU20000034U0 (en) The tune-changing mechanism of the kantele
ITRC20010003A1 (en) "FUMANELLO"
IT1314647B1 (en) ANTI-FOG DEVICE
SE0002922D0 (en) Pharmaceutically useful compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application